Real-World Use and Outcomes of Olaparib: a Population-Based Cohort Study
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Real-World Use and Outcomes of Olaparib: a Population-Based Cohort Study
Authors
Keywords
-
Journal
Targeted Oncology
Volume 13, Issue 6, Pages 725-733
Publisher
Springer Nature
Online
2018-11-17
DOI
10.1007/s11523-018-0604-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Abstract P3-17-03: Concordance of real world progression free survival (PFS) on endocrine therapy as first line treatment for metastatic breast cancer using electronic health record with proper quality control versus conventional PFS from a phase 3 trial
- (2018) CH Bartlett et al. CANCER RESEARCH
- First PARP Inhibitor Ok'd for Breast Cancer
- (2018) Cancer Discovery
- Olaparib in German routine clinical practice: Updated interim results of the non-interventional study C-PATROL.
- (2018) Frederik Marme et al. JOURNAL OF CLINICAL ONCOLOGY
- Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
- (2018) Kathleen Moore et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Swedish cause of death register
- (2017) Hannah Louise Brooke et al. EUROPEAN JOURNAL OF EPIDEMIOLOGY
- Real-world Data for Clinical Evidence Generation in Oncology
- (2017) Sean Khozin et al. JNCI-Journal of the National Cancer Institute
- Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
- (2017) Eric Pujade-Lauraine et al. LANCET ONCOLOGY
- Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
- (2017) Mark Robson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Real-world Data for Clinical Evidence Generation in Oncology
- (2017) Sean Khozin et al. JNCI-Journal of the National Cancer Institute
- PARP inhibitors as precision medicine for cancer treatment
- (2017) Yi Du et al. National Science Review
- The First Decade with the Swedish Prescribed Drug Register - A Systematic Review of the Output in the Scientific Literature
- (2016) Susanna M. Wallerstedt et al. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY
- Opportunities and challenges in leveraging electronic health record data in oncology
- (2016) Marc L Berger et al. Future Oncology
- Healthcare Utilisation and Drug Treatment in a Large Cohort of Patients with Inflammatory Bowel Disease
- (2016) Thomas Cars et al. Journal of Crohns & Colitis
- DNA repair targeted therapy: The past or future of cancer treatment?
- (2016) Navnath S. Gavande et al. PHARMACOLOGY & THERAPEUTICS
- Olaparib: First Global Approval
- (2015) Emma D. Deeks DRUGS
- 2755 First real life data on Olaparib in BRCA1/2 mutated Platinum-Sensitive Relapsed (PSR) Epithelial Ovarian Cancer (EOC) in France: Analysis of 52 patients (pts) enrolled in the French Temporary Authorization for Use (ATU)
- (2015) T. De La Motte Rouge et al. EUROPEAN JOURNAL OF CANCER
- 19th International Meeting of the European Society of Gynecological Oncology (ESGO 2015)
- (2015) INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- Challenges in economic modeling of anticancer therapies: an example of modeling the survival benefit of olaparib maintenance therapy for patients with BRCA-mutated platinum-sensitive relapsed ovarian cancer
- (2015) Robert Hettle et al. JOURNAL OF MEDICAL ECONOMICS
- Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial
- (2014) Jonathan Ledermann et al. LANCET ONCOLOGY
- Bringing in health technology assessment and cost-effectiveness considerations at an early stage of drug development
- (2014) Bengt Jönsson Molecular Oncology
- Extraction of Electronic Health Record Data in a Hospital Setting: Comparison of Automatic and Semi-Automatic Methods Using Anti-TNF Therapy as Model
- (2013) Thomas Cars et al. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY
- External review and validation of the Swedish national inpatient register
- (2011) Jonas F Ludvigsson et al. BMC PUBLIC HEALTH
- The completeness of the Swedish Cancer Register – a sample survey for year 1998
- (2008) Lotti Barlow et al. ACTA ONCOLOGICA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started